Enlivex Therapeutics Accounts Payable

Enlivex Therapeutics (ENLV) currently reports a accounts payable of $3.8M as of December 2025. That compares with $810K in the prior-year period — up 369.5% year over year. Use the charts on this page to explore Enlivex Therapeutics's accounts payable history and peer comparisons.

Enlivex Therapeutics's accounts payable increased from $810K to $3.8M — a 369.5% year-over-year increase (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Enlivex Therapeutics reported $3.8M in accounts payable as of December 2025. That compares with $810K in the prior-year period — up 369.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $3.8M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Enlivex Therapeutics, and consider following ENLV for alerts when major investors trade the stock.

Enlivex Therapeutics is classified in the Healthcare sector. On accounts payable, it currently shows $3.8M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ENLV with unrelated industries.